Abstract | Common cardiovascular diseases, such as atherosclerosis and congestive heart failure, are exceptionally complex, involving a multitude of environmental and genetic factors that often show nonlinear interactions as well as being highly dependent on sex, age, and even the maternal environment. Although focused, reductionistic approaches have led to progress in elucidating the pathophysiology of cardiovascular diseases, such approaches are poorly powered to address complex interactions. Over the past decade, technological advances have made it possible to interrogate biological systems on a global level, raising hopes that, in combination with computational approaches, it may be possible to more fully address the complexities of cardiovascular diseases. In this Review, we provide an overview of such systems-based approaches to cardiovascular disease and discuss their translational implications.
Introduction
The past several decades of cardiovascular research have been dominated by reductionistic approaches. These stra tegies have led to the identification of many molec ules and regulatory mechanisms involved in normal and patho logical cardiovascular states, and the roles of hundreds of these molecules have been studied in vivo using targeted pharmacological or genetic manipulation in various animal models. Nonetheless, many important questions about cardiovascular diseases, particularly those relating to its biological complexity, remain unanswered. For instance, the fundamental causes of common complex forms of cardiovascular disease are still unknown. An illustration of our ignorance comes from genomewide association studies (GWAS) in patients with coronary artery disease (CAD) that have revealed about 30 genetic loci or genes that are likely to be the mostimportant genetic diseasesusceptibility factors. 1 Some of these genes had been identified previously, but the majority were not connected to any known risk factor or signaling pathway that contributes to the development of atherosclerosis. A similar challenge exists for heart failure, for which GWAS revealed only a few genetic loci or genes, of which only a small proportion had a clear biological role in the disease.
Over the past one or two decades, scientists have wit nessed a revival in interest in systemsbiology approaches to the study of multicomponent, biological processes. [2] [3] [4] [5] [6] [7] [8] This revival is, in part, a result of the Human Genome Project and related technological developments, such as geneexpression arrays, that have enabled researchers to interrogate biological systems at a global level. In addi tion, new computational and mathematical approaches, such as network modeling, are being developed to extract biological information from data obtained by highthroughput analyses and other data. In addition, the realization is growing that reductionistic approaches alone will not allow us to fully address phenomena such as the beating of the heart or the development of an athero sclerotic plaque. For those working in the field of cardio vascular medicine, the current interest in systemsbased approaches was preceded by Denis Noble's realization several decades ago that the narrowly focused analysis of individual transporters could never explain the rhythms of a beating heart. [9] [10] [11] The urgent need for systemsbased approaches becomes apparent as we wrestle with the clinical burden of CAD and congestive heart failure (CHF). The life time risk of CAD is about 50% in Western countries and, although effective preventative treatments for CAD (such as cholesterollowering drugs) are widely used, the incidence of the disease has decreased only slightly over the past two decades. 12 Notably, the current obesity epidemic is predicted to increase the incidence of one of the major risk factors for CAD-type 2 diabetes mellitus -and, therefore, the incidence of atherosclerosis will also increase. CHF affects one in five individuals in the USA during their lifetime, and the incidence of CHF is rising because of the rapidly aging population. 13 The high preva lence of CAD and CHF impose enormous human, social, and economic costs in both developed and developing countries. In this Review, we explain 'systemsbased' approaches to cardiovascular disease and discuss their translational implications.
is, that a complex system has intrinsic novel proper ties that cannot be derived directly from the additive effects of its individual parts. 4 Take, for example, the action potential of a cardiomyocyte, which requires the co ordinated action of more than 20 different ion transporters and channels. Studying these individual components might provide information about their role in a specific aspect of the action potential, but to fully appreciate actionpotential generation, scientists require an understanding of how these components function together over time and need to integrate them into a quantitative mathematical model. [14] [15] [16] [17] A striking example of the importance of studying multiple components simultaneously is the discovery of induced pluripotent stem cells. 18 In their ground breaking study, Takahashi and Yamanaka hypothesized that multiple factors would be needed for reprogramming an adult somatic cell into a pluripotent stem cell, and they successfully identified the required factors by examining various combina tions of candidate transcription factors. Their approach would not have worked if they had tested indivi dual candidates separately.
A typical systemsbased study involves the following five steps. 4, 19 The first objective is to define the 'system' to be examined. Such a system could be an organelle, organ, or organism. The second step is to identify the compo nents of the study system, which could include mRNA transcripts, noncoding RNAs, small interfering RNAs, proteins, small molecule metabolites, membrane poten tials, or other physiological or pathological parameters that are relevant to the study. Thirdly, investigators need to determine how these components interact with each other, either by conducting experiments or by search ing published literature. For example, protein-protein interactions can be defined by coimmunoprecipitation ( Figure 1 ) and functional relationships between genes can be investigated using coexpression studies (see
Key points
■ The cardiovascular system is a complex network of organs and cell types, each with specialized, but highly coordinated, functions; therefore, cardiovascular disease is complex in etiology and manifestation ■ A systems-based approach aims to reveal the architecture and the emerging properties of a complex network by uncovering the relationships among the constituents and establishing global governing principles ■ Current advances in bioinformatics, genomics, proteomics, and metabolomics offer an excellent opportunity to use systems-based analysis to dissect complex networks involved in cardiovascular physiology and diseases ■ In the study of cardiovascular diseases, systems biology compliments genetic analyses, such as genome-wide association studies, by establishing the underlying mechanisms and the functional significance of the candidate genes ■ 'Systems genetics' is a new approach based on the systems-based analysis of genetic variants and phenotypic spectra at various levels, spanning from gene expression to organ physiology ■ By establishing the molecular components and gene networks for the cardiovascular system, systems biology can help to develop effective and personalized diagnostic tools and therapies for cardiovascular diseases below). The fourth step is to model the dynamics of the network mathematically to understand how the inter actions between network components change over time or in response to various perturbations, and to attribute emerging properties to the targeted system. Fifth, the models should be validated using specific experimental perturbations, which can also be used iteratively to refine the models. 4 One of the hallmarks of systems biology has been the utilization of mathematics and computation to develop models and analyze large datasets. [20] [21] [22] [23] In general, multi parametric data are collected after an experimental perturba tion or during multiple states in which the system can exist, and are subjected to various kinds of computational filtering (such as removal of outliers and normaliza tion). Statistical analyses are often required to identify significant differences between states. The resulting lists or matrices can then be subjected to Figure 1 | Construction of a protein-interaction network. The following approach was used by Behrends et al. to study autophagy, 109 a cellular process that has been linked to various cardiovascular diseases. 110 Proteins previously known to be involved in authophagy (red circles with letters) were retrovirally expressed as Flag-HA 52 fusion proteins in cultured cells. Proteins and their binding partners (numbered blue circles) were then precipitated using anti-HA antibodies and identified by mass spectrometry. An additional set of interacting proteins that were identified in the first experiments acted as secondary baits and was processed identically. This 'reciprocal' analysis allowed validation of the original findings and identified connections between the baits of the first set of experiments as well as with other proteins (numbered yellow circles). The network was then further refined using mutagenesis and RNA interference. Abbreviation: HA, hemagglutinin. REVIEWS various kinds of mathematical analyses to identify bio logically meaning ful patterns. For example, a particu larly important application of systems biology has been the modeling of oscillating systems, such as the cell cycle and bio logical clocks. 24, 25 Perturbations to a system and interactions between its elements can be modeled using various mathe matical equations, or they can be repre sented as simplified networks. 25 With the flood of genom ics data from various highthroughput technologies, much emphasis has been placed on the development of statistical methods that can be used to identify functional relationships. For instance, one can ask whether lists of biological parameters (such as changes in gene expression in pathologic states) are enriched for known pathways. 19 Role of high-throughput techniques One of the mostimportant factors fueling the current interest in systemsbased studies was the development of a variety of powerful highthroughput technologies that can generate large datasets ( Table 1 ). The first of these technologies was the geneexpression array, which was developed in the 1990s and allows global quantification of mRNA transcripts. [26] [27] [28] [29] [30] [31] [32] [33] Geneexpression arrays were originally expensive, but the cost of performing an array experiment has now fallen to nearly that of studying a handful of genes by common methods such as quantita tive PCR. Similarly, advances in highthroughput mass spectrometry have made it possible to examine the levels of hundreds or thousands of proteins or metabolites in a single experiment. [34] [35] [36] [37] A striking example of the utility of 'metabolomics' is the discovery in 2011 of a novel molecu le that promotes atherosclerosis. 38 GWAS are another form of 'highthroughput biology' that is relevant to systemsbased approaches. In GWAS, the statistical association between common genetic vari ants in the population and complex phenotypical traits is examined. Alone, GWAS do not have sufficient power to demonstrate interactions among genes or between genes and the environment. However, GWAS can be combined with other techniques, such as expression quantitative trait locus (eQTL) mapping, to provide information about the functions of the loci and genes associated with disease ( Figure 2 ). The power of eQTL mapping was demonstrated in a study by Small and col leagues, who showed how an eQTL acts as a 'master regulator' that controls a variety of loci associated with metabolic syndrome. 39 Particularly important for the progress of systems biology have been the advances in DNA sequencing that, since the time of the Human Genome Project, have resulted in an over 100,000fold decrease in cost of sequencing per base. The reduction in cost has even enabled research ers to use nextgeneration sequencing, which is based on massively parallel sequence analysis, to search for rare genetic variants that contribute to complex traits. Indeed, sequencing the entire exome (that is, all proteincoding exons) after isolating coding regions with hybridization techniques is now fairly straightforward. 40 The sequencing revolution has also made examination of DNA methylation (the 'methylome') or chromatin states (using chromatin immuno precipitation followed by sequencing, also known as ChIPSeq) possible on a global scale. 40 
Biological networks
An important concept that has emerged over the past decade is that biological elements, such as macro molecules and metabolites, do not function in isola tion, but instead form 'networks' with characteristic topologies. 2, 7, 20, [41] [42] [43] [44] [45] Network science simplifies complex systems by summarizing the elements (known as 'nodes') and their interactions (termed 'edges'), and by identify ing functional groups (called 'modules'). The concept of biological networks first arose when metabolic pathways were represented as graphs, with metabolites as nodes and their interactions (enzymatic conversions) as edges. 45 Biological networks can include interactions between molecules (DNA, transcripts, proteins, metabolites), cell organelles, cells, tissues, and even between individuals and the diseases they have. 19, 42 A challenge of systems biology is to model networks at each scale-from gene to organism to disease-and then connect orthogonal datasets.
Networks can be constructed on the basis of published biological literature, from results of unbiased experi mental studies, or by a combination of the two approaches. In experimental studies, researchers can aim to identify physical interactions between components (as in proteinprotein complexes; Figure 1 ) or to examine correlations between components (for example, between mRNA levels after a series of experimental perturbations; Figure 3 ).
Many biological networks seem to have a topology described as 'scalefree' , in which most nodes have few links, but a small subset of nodes has many links (these subsets are also known as 'hubs'). Scalefree networks are found throughout biology, and some investigators believe that their architecture confers an evolutionary advantage in that it exhibits biological robustness because multi ple alternative pathways exist to get from one node to another. 46, 47 This redundancy also makes networks adapt able to changing environments, for example, by minimiz ing the number of steps required for interconversion of various food substances.
Another important consideration in network studies is the degree to which networks are preserved across various phenotypic conditions (such as between sexes, tissues, and species). This problem has been addressed in several studies, [48] [49] [50] and algorithms to examine network preser vation have been developed. 51 For instance, whereas net works are largely conserved between sexes, they diverge across species, even in species as closely related as humans and chimpanzees. 51 Network divergence can provide useful insights into the similarity or differences between model systems that might not be obvious from exami nation of their component parts.
Studying cardiovascular diseases
As a result of the diversity in developmental origin, struc ture, and function of the heart and blood vessels, mapping the complex interactions within the cardiovascular system can be challenging. This task is further compli cated by the hierarchy within each component, consider ing the potential interactions between genes, 38 proteins, macromolecular complexes, organelles, cells, and organs in the cardiovascular system.
17,52
Pathogenesis of cardiovascular diseases Atherosclerosis, a chronic inflammatory disease of the large arteries, is the primary cause of CAD. 12, 53, 54 Most forms of CAD result from metabolic disturbances that include elevated blood pressure, increased levels of low density lipoproteins, decreased highdensity lipoprotein levels, and insulin resistance ( Figure 4 ). The accumulation of oxidized LDL in the subendothelial space initiates an inflammatory response that involves the recruitment of monocytes and, subsequently, lymphocytes to the vessel wall. The development of advanced atherosclerotic lesions is a chronic process that generally takes decades. The most important clinical consequence of athero sclerosis is myocardial infarction, a thrombotic occlusion of a coro nary blood vessel that is often precipitated by the rupture or denudation of a lesion and the exposure of prothrom botic tissue factor. If an individual survives a myocardial infarction, the damage can result in cardiac abnormali ties, such as arrhythmia or pathological remodeling, with eventual CHF. 12, 53, 54 The past decade has seen an explosion of research into the pathogenesis of CHF. 13, 55, 56 CHF can result from endo genous defects within the cardiomyocytes themselves or from external factors that place excessive demands upon the heart (Figure 4) . Examples of intrinsic factors are dis eases such as genetically mediated dilated cardio myopathy or hypertrophic cardiomyopathy. External factors that can lead to heart failure include myocardial infarction, uncontrolled hypertension, metabolic dis orders, or hor monal disorders such as hyperthyroidism. Collectively, these factors increase biomechanical stress and lead to a host of changes at the molecular and cellular level ( Figure 4) . βadrenergic blockade and inhibition of the renin-angiotensin-aldosterone system are now the stan dard regimens in the management of patients with CHF. Despite much progress, CHF remains a leading cause of morbidity and mortality, and no therapy is available that can effectively reverse disease progression.
The many environmental factors that affect the develop ment of CAD and CHF play on the background of hun dreds of genetic factors that, although individually exerting modest effects, together dramatically influence disease susceptibility. 12 Additional complexities arise when con sidering agerelated effects and differences between sexes or ethnic groups (Figure 4) . If the diseases resulted simply from the sum of the individual contributing factors, a reductionistic approach might eventually lead to a detailed understanding of susceptibility and therapeutic responses. However, given the prevalence of interactions among genes or between genes and the environ ment observed in simple model organisms or cultured cells, morecomplex interac tions are a certainty. 57 Systems biology offers an approach to meet such challenges by attempting to decipher the global principles that govern these complex biological systems.
Cardiovascular networks
A study by Ramsey and coworkers illustrates the approach of experimentally perturbing a biological system and subsequent mathematical modeling of the REVIEWS interactions in the system. 58 The investigators explored the macrophage transcriptional network mediated by stimulation of Tolllike receptors (TLRs), which have been implicated in the development of athero sclerosis. 53 TLRs recognize a variety of pathogenassociated molec ules and possibly certain endogenous molecules. Upon ligand binding, TLRs signal through adaptor molecules, such as Toll-interleukin1 receptor domaincontaining adapter molecule 1 (TICAM1; also known as TRIF) and Myd88, and then parallel crosstalking signaling pathways. These signaling pathways initiate a cellular program that leads to the differential expression of over 1,000 genes, including hundreds of transcription factors. Although these differentially expressed genes were known, the network of interactions between transcription factors and mRNA levels has proved difficult to address for several reasons. Firstly, the network is combina torial, involving multiple large datasets. Secondly, many transcription factors are regulated by post translational modifications, such as phosphorylation. Thirdly, unlike in yeast, creating targeted genetic perturbations in mammals is not feasible on the large scale that is required for some systemsbiology studies, and siRNAmediated knockdown of proteins tends to stimulate TLR signal ing pathways. Instead, the investigators combined two types of data to infer the network. First, they performed computational scanning of promoter sequences of clus ters of coexpressed genes for known transcriptionfactor binding sites. They then used a signal processing tech nique called 'expression dynamics analysis' and modeled timecourse expression data to best fit mRNA levels of a transcription factor with the expression of its potential target genes.
The team used a series of singlegene perturbations to obtain the primary expression data. They treated primary bonemarrowderived macrophages from five strains of mice (the wild type and four strains with genetic muta tions) with six different TLR agonists and performed wholegenome expressionarrayanalyses at multiple time points after stimulation (0-48 h). In total, 95 differ ent datasets from various combinations of strains, stimuli, and time points were obtained. The set of differentially expressed genes was clustered, promoter sequences of each gene were scanned for transcriptionfactor binding sites, and the temporal expression patterns of transcrip tion factors and target genes were compared to identify potential causal influences. When integrated, the results provided a broad picture of the dynamic transcriptional program of the TLR network. Many previously known interactions were identified, and a small subset was confirmed experimentally. Altogether, the connections between 36 transcription factors and 27 clusters of target genes were recognized. The integration of time course data with promoter scanning clearly provided a more detailed picture of the interactions than either technique would have provided alone. This general approach has now been applied to numerous mammalian systems, including cell signaling, oncogenesis, development, and common complex diseases. 24, 25, [59] [60] [61] [62] The concept of networks can also be applied to very complex traits, such as the physiological relationships between normal biological features and those observed 63 The researchers first showed that significant variation existed in traits such as blood pres sure, heart rate, ventricular shortening, ventricular mass, and enddiastolic dimension among inbred strains of mice. To understand the functional relationships between these traits, the team examined a series of recombinant inbred strains. The traits in these strains differed because of subtle, naturally occurring genetic variations. If traits shared genetic factors or showed homeostatic interac tions, correlations would be observed among the set of recombinant inbred strains studied, allowing for the modeling of a network in which the nodes are 'traits' and the edges are 'correlations' . The network was con sistent with previous physio logical studies 10 and was further elaborated by examining the effects of certain pathologic perturbations using genetically engineered mice or mice treated with pharmaco logical agents. 63 This study emphasizes the utility of multiple genetic perturba tions, rather than singlegene perturbations, for the analy sis of complex systems. Singlegene perturba tions, such as in transgenic mice, allow causality to be established, but have limited power to resolve the pleiotropic and homeostatic interactions resulting from the perturbation.
Systems genetics of cardiovascular traits
Any natural population contains many thousands of variations that perturb gene expression or gene sequence. Some of these variations contribute to disease suscepti bility. The concept of 'systems genetics' is simple: monitor the effects of natural variations at molecular levels (for example, mRNA, protein, or metabolite levels) and then integrate these data with clinical phenotypes ( Figure 5) . 19, 64, 65 For example, one might examine gene expression in monocytes from 100 individuals with atherosclerosis and 100 healthy controls, and then ask whether statistically signifi cant differences exist between the two groups. With a dense singlenucleotide poly morphism (SNP) map of the DNA from both groups, one could also map eQTLs and investigate whether these loci match disease susceptibility loci identified in GWAS (Figure 2) . Furthermore, one could use the gene expression data to model coexpression networks and determine which modules are correlated with athero sclerosis. Systems genetics, therefore, allows the integra tion of molecular and clinical data in a powerful way.
Transcript levels have been examined as a function of genetics in a number of clinical and animal studies and have yielded promising results. 8, 31, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] Causality is an important concept in network model ing. For example, coexpression networks are based simply on correlation and, as such, are considered 'un directed' . However, by making certain assumptions (as described below) or by introducing specific pertur bations of a network component, investigators can model causal interactions and derive a 'directed' network. For instance, in the above networks, 8, 31, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] siRNA knock down or gene targeting was used to establish causality with respect to certain nodes in the network. Given such causal anchors, and knowing the nodes in a system as well as their variances, deriving a set of equations that describe the causal relationships of the various elements is theoretically possible using structural equation modeling or Bayesian analysis. [76] [77] [78] In systems genetics, DNA can serve as a causal anchor in that information flows from DNA to mRNA tran scripts, proteins, metabolites, and clinical traits, and this concept has been used to broadly model directed bio logical networks (Figure 3) . 66, 79 An example is the study by Gargalovic and colleagues, 80 who used gene coexpression analysis to model an inflammatory network for responses of human endothelial cells to oxidized phospholipids, which are thought to promote atherosclerosis by stimulat ing endothelial cells to produce inflammatory cytokines such as interleukin 8 (IL8). Gargalovic et al. exploited common genetic variations in the human population. 80 In preliminary studies, the researchers investigated common variations in inflammatory responses of endothelial cells isolated from various individuals using IL8 immuno assays. The results indicated that striking differences in responses existed, with some individuals producing essentially no IL8 in response to oxidized phospholipids, whereas other individuals showed a more than 10fold induction of IL8. The investigators then used micro arrays to measure global gene expression in endothelial cells isolated from 12 different individuals and observed that over 1,000 genes were differentially regulated by the treatment with oxidized phospholipids. These variations in the sampled population were then used to construct a gene coexpression network comprised of 15 modules of highly connected genes. The identified modules were significantly enriched in genes for previously known pathways (although the role of these genes in this context was not previously recognized), including modules corres ponding to two different arms of the unfolded protein response. In addition to confirming key pathways involved in the inflammatory response, the network also predicted regulatory mechanisms and identified previously unknown gene functions. 70, 80 Romanoski and colleagues extended the study of Gargalovic et al. by examining a total of 166 primary endo thelial cell lines that they genotyped using high density SNP arrays. 80, 81 This larger dataset enabled the team to integrate genetic associations, including novel trans acting regulatory pathways, into their network model. Their predictions on the basis of this model were validated by siRNA knockdown and over expression of the relevant genes, such as predicted regulators of other genes. 81 In a systemsgenetics study of CHF, Cook and col laborators examined the regulation of left ventricular mass (LVM) in a panel of recombinant inbred rat strains derived from the Brown Norway rat and the spontane ously hypertensive rat (SHR). 82, 83 The hearts were exam ined for LVM, and global geneexpression profiles were determined. The genetic loci contributing to LVM were mapped using linkage analysis (that is, by asking which regions of the genome were significantly associated with the traits of interest). The researchers identified a region on rat chromo some 17p14 that was associated with LVM. The many genes contained in this region were screened for those that showed strong ciseQTL characteristics. The gene encoding osteoglycin stood out as a strong candidate, and subsequent knockout studies in mice con firmed its role in LVM. The investigators then went on to examine mRNA levels in human heart biopsies from patients with aortic stenosis. Of all candidates tested, osteoglycin expression had the highest correlation with LVM measured by echocardiography. 82, 83 These studies 82, 83 emphasize the utility of combining animal models with clinical investigations for understanding pathways that contribute to complex traits.
Systems biology and GWAS
Large GWAS have been performed for CAD, CHF, and various related traits such as hyperlipidemia and hyper tension. 1, 84, 85 A large number of genetic loci have been 
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identified but, collectively, these loci explain only a small fraction of cases, and the underlying causal gene often cannot be unambiguously identified owing to correla tion structure (or linkage disequilibrium) among SNPs at a locus (that is, because of population history, SNPs at a parti cular locus are often highly correlated). Examining eQTL ( Figure 2 ) at a genetic locus associated with a clinical trait can help prioritize gene candidates and suggest causal mechanisms of disease. For example, a novel genetic locus strongly associated with the regula tion of LDLcholesterol levels was identified on human chromosome 1 in several GWAS. 86 The locus contained several candidate genes in linkage disequilibrium with the peak SNP. To narrow the search for the responsible gene, Musunuru and colleagues examined the genes for potential eQTL controlled by the SNP. 86 Combining eQTL mapping with various molecular analyses, the researchers identified SORT1 as the gene underlying the phenotype of this locus and validated their findings by overexpressing SORT1 in mice using an adenoassociated viral vector. Their results indicated that SORT1 overexpression decreased VLDL and apolipoprotein B secretion. 86 Another example of the use of eQTL mapping to help provide mechanistic information is a study of the Kruppel like factor 14 (KLF14) transcription factor locus, which was originally found in GWAS to be implicated in certain traits associated with metabolic syndrome. 39 Reasoning that KLF14 variation might control target genes, Small et al. identified 10 additional genes with transcript levels that correlated with those of KLF14 in adipose tissue of patients with metabolic syndrome and showed that these transcripts partly mediated the effects of KLF14. Several of these new loci proved to contain SNPs that were also associated with traits of metabolic syndrome.
Beyond eQTL analyses, network modeling can be com bined with GWAS to provide information about novel GWAS 'hits' . A case in point is the large GWAS for CAD conducted by Schunkert and colleagues, who identified a total of 26 loci. 1 Most of these genes had no connec tion to any signaling pathway or risk factor previously associated with the disease, but several of the genes were found in networks modeled for endothelial cells under oxidative stress, immediately providing candidate path ways and interacting genes. 57, 80 For instance, the poorly understood NT5C2 gene encodes a nucleoside mono phosphate phospho hydrolase which, among other sub strates, can dephosphorylate noncyclic AMP. How NT5C2 may contribute to atherosclerosis is totally unknown, but the finding that it occurs in an inflammatory module of a human endothelial cell network ( Figure 6 ) suggest pos sible mechanisms or interactions with other genes through which NT5C2 might affect atherosclerosis progression.
Clinical implications

Network medicine
The concept of 'network medicine' is built upon the hypothesis that perturbations of biological networks, owing to injury, infection or other pathological triggers, are the underlying causes of complex human diseases. 5, 42 Some investigators believe that systemsbased approaches might not only complement reductionistic approaches but that they will be essential to effectively translate the vast amounts of currently available biological information into treatment modalities for common diseases.
How will these novel insights translate into improved health? The translation will likely take several forms. For instance, systemsbased approaches might predict new diseasecausing genes, identify individuals who are at increased risk of disease or complications, optimize exist ing therapies in target populations, or lead to the design of completely novel therapies that could not have been developed without a systemsbased approach. Whereas diseaseassociated genes can often be identified with 'tra ditional' genetic approaches, systembased approaches have the potential to identify novel disease genes based on diseasenetwork classification. Disease networks identify the proteins that interact directly with known diseaseassociated genes and with the genes and proteins (or cellular components), the expression, function, or localization of which is regulated along with the disease associated gene. Such a network can then be used to predict new diseasecausing genes since proteins within a disease network that interact with (or are regulated by) diseaseassociated genes have an increased likelihood of being diseasecausing genes themselves. Using known gene mutations as edges to link disease nodes that share the same mutations, Barabási and col laborators have built the first human disease network, which has many interesting features and led to some unexpected findings. 87 One of these features is that a large number of human diseases cluster in a single component in the disease network, suggesting a common under lying mechanism of a diverse collection of human diseases that involves abnormalities in a specific, critical subset of genes. Unexpectedly, the network also suggests that most diseasecausing genes are nonessential and do not preferentially encode hub proteins.
Alternatively, genes associated with a particular disease can be analyzed in a diseasespecific gene network. In both general diseasenetwork analyses and disease specific genenetwork analyses, investigators can evaluate the potential interdependence of cardiovascular diseases and CHF with other diseases that might share common pathogenic mechanisms, which could lead to the discov ery of previously unknown causal genes associated with cardiovascular disease and CHF. 52 Diagnostics Although molecular diagnosis is less common in cardio logy than in oncology, several examples of the successful development of assays that aid in clinical decision making exist for this field. For instance, approximately 40% of patients who undergo heart transplantation experience at least one episode of acute rejection in the first year after transplantation. In most cases, these rejection episodes are reversible when immunosuppression is intensified. However, immunosuppressive drugs have substantial adverse effects, and rejection can only be diagnosed by endomyocardial biopsy-an invasive procedure that can be painful, expensive, and damaging to the trans planted heart. To circumvent this problem, investigators used microarrays to analyze geneexpression patterns in peripheral leukocytes of patients who had under gone a heart transplantation and revealed specific pat terns that identified individuals who were experiencing a rejection. 88 The network analysis identified 11 critical genes, the expression of which can be measured with the commercially available AlloMap® assay (XDX, Brisbane, CA, USA) using quantitative reverse transcriptase PCR. AlloMap® testing can reduce the number of invasive bi opsies required to monitor selected patients and has a major impact on the way immunosuppression of trans plant recipients is monitored. 89 Similar efforts are ongoing in patients with CAD or CHF to determine whether gene expression monitoring can identify disease state and optimize treatment. 90 
Genetic testing
Classically, genetic information is used to identify indivi duals who are genetically predisposed to disease so that interventions can be devised to reduce the incidence and severity of disease. Given that consumers can now purchase a directtoconsumer (DTC) genomewide diseaseriskprofiling kit at their local pharmacy, has the era of personalized genetic risk prediction arrived? These kits quantify genetic risk of a host of medical conditions, but what will the public do with the information, and will it trigger an epidemic of needless screening, treatment, or both? Disease penetrance can vary highly within atrisk populations, presumably secondary to variation in modifier genes or exposure to environmental factors that preci pitate the disease (for example, smoking or ele vated LDLcholesterol levels, among others), and their response to interventions aimed at reducing disease risk. Even more concerning is the lack of regulatory oversight for these selfadministered tests. Substantial concerns exist within the scientific community about the valid ity, clinical utility, and marketing claims of many com merciallyavailable DTC test kits. One could envision an utopia where individuals use this genetic diseaserisk information to improve their healthrelated behavior, but is this expectation realistic? Bloss et al. surveyed over 2,000 individuals who voluntarily purchased a DTC genetic risk kit and found that genetic testing did not result in any statistically significant shortterm changes in psychological health, dietary fat intake, or exercise behavior. 91 Overall, the testing did not increase anxiety levels, but the severity of testrelated distress correlated with increasing estimated average lifetime risk of any condition, suggesting the response was proportional to the perceived risk. Worryingly, individuals with higher composite measures of alldisease risk indicated their intention to use more medical testing in the future, vali dating concerns that this form of testing could open the flood gates to inappropriate disease screening and the costs associated with these tests. Given concerns regard ing overtesting and overutilization of medical resources by most Americans, easily accessible and unregulated tests could burden an already overwhelmed medical system. Although DTC genomewide diseaserisk profil ing might seem a revolutionary advance in our approach to medicine, the impacts of such testing on psychology, health, and society are uncertain. However, one issue experts agree on is that if this genetic information is to be applied in a costeffective way, models that predict highrisk individuals more accurately will be required, which stresses the importance of developing better diseasespecific networks.
Pharmacogenomics
Even if the use of the vast sums of genetic information that is currently available is problematic, surely such data could be used to optimize existing therapies in target populations. Integrating genetic information with thera peutic efficacy is the foundation of personalized or strati fied medicine, of which pharmacogenomics is the classic example. 92, 93 Pharmacogenomicallyguided dosing has been proposed as an ideal way to improve drug efficacy and reduce adverse effects. Numerous sequence variations in specific genes are associated with altered sensitivity or metabolism of common medication. The best example of this is pharmacogeneticallyguided improvements in warfarin dosing, since monitoring anti coagulation therapy is time consuming and expensive, and warfarin overdoses are associated with a large number of adverse reactions. 94, 95 However, dosing based on polymorphisms in the gene encoding the vitamin K epoxide reduc tase complex 1 (VKORC1), which partially determines sensitivity of patients to warfarin, neither reduced the incidence of adverse events nor reduced outofrange bloodclotting times (measured using the international normalized ratio). These results might be a moot point, as new direct thrombin inhibitors are likely to replace the routine use of warfarin in anticoagulation therapy. 96 Efforts to develop pharmacogenetic tools in CHF have also encountered problems. One of the fundamen tal lifeprolonging therapies for patients with CHF is the administration of βblockers, but predicting which patients will respond to this class of medications is impos sible with currently available tools. Furthermore, why some βblockers work whereas others do not is unclear. Conflicting data have been reported on the utility of using polymorphisms within genes that are involved in the metabolism or action of βblockers to predict thera peutic outcome. However, most investigators have not been able to demonstrate differences in survival among patients with CHF who were stratified on the basis of genetic polymorphisms associated with the pharmaco kinetics or pharmacodynamics of βblocker therapy. [97] [98] [99] Similarly, given the prevalence of hyperlipidemia in the general population and the common use of statins, clini cians hoped that pharmacogenomics would be a useful tool to distinguish patients in whom statin therapy is beneficial from those who have serious adverse effects. 100 Although genetic polymorphisms have been identified that are associated with reductions in cardiovascular events and lipoprotein levels, the fairly small magnitude of these reductions have not influenced clinical decision making as it relates to statin therapy. 101, 102 Although pharmacogenomicallyguided dosing of cardiovascular medications has the potential to improve patient health while decreasing healthcare costs compared with standard dosing regimens, this potential has yet to be realized. The reasons for the limited success of this approach are speculative, but perhaps attempts to adjust drug doses on the basis of a single polymorphism are subject to the same limitations as singlegene approaches are to other aspects of biology. Highthroughput approaches that integrate information from GWAS can be used to identify multiple genetic variations that predict drug responses better. For example, Shu et al. integrated diverse data to demonstrate that genetic variation in the organic cation transporter 1 (OCT1) affects the action of metformin, a drug widely used to treat patients with diabetes. 103 Metformin enters hepatocytes and enterocytes predominantly via OCT1 and a number of human vari ants in OCT1 that are associ ated with reduced transporter activity have been characterized. 103 The clinical signifi cance of the interaction between OCT1 polymorphisms and metformin activity has yet to be fully characterized, but this general approach could be used to determine responders to a specific pharmaco logical therapy and, ultimately, allow personalized tailoring of therapy on the basis of a patient's genotype. 104 Nonetheless, these data provide a cautionary note that the application of pharmaco genomic information in clinical practice is unlikely to be as straightforward as investigators and physicians alike had hoped, and that systemsbased approaches may be required here as well to ensure successful translation to the clinic.
Drug discovery
In 1996, 53 new molecular entities were approved by the FDA. Ten years later, this number had dropped to 18 and has remained at similarly low levels ever since. 105 The explanation for this drop in approval of new thera peutics is likely to be multifactorial, but might largely be because of the limited number of novel drug targets that are being identified as scientific fields mature and because of a shift in emphasis to biological therapies. Drug dis covery has traditionally been 'targetfocused' . However, complex diseases can sometimes only be understood when viewed from the perspective of the multiple genetic and environmental factors, and-importantly-when taking into account their interactions. Techniques that integrate genetic, expression, and clinical data to eluci date networks underlying disease thus provide a powerful approach to developing novel therapeutic interventions, since they identify critical genes and interactions between genes that might serve as drug targets or reveal adverse effects. 8 Analysis of these networks can lead to the discov ery of novel drugs or novel uses of existing drugs based on targeting multiple genes within a network.
An example of how a systemsbased approach that inte grates data from multiple sources can lead to the design of a new drug can be found in the field of cardiac arrhyth mia. 106 Ventricular arrhythmia, and ventricular fibrilla tion in particular, is a leading cause of sudden cardiac death. Fibrillation is generated by the deterioration of organized ventricular electrical activity into fragmented electrical waves that lead to ineffective contraction. By integrating experimental evidence and computer model ing of electrical activity, Garfinkel et al. concluded that fibrillation is created and sustained by the property of restitution of the cardiac actionpotential duration. 107 The restitution properties of the cardiac action potential duration and conduction velocity contribute to the breakup of reentrant wavefronts during cardiac fibril lation, independent of preexisting electrophysiological heterogeneities in the tissue. This inference enabled the team to identify the 'ideal' drug to correct the abnor malities in restitution that drive cardiac fibrillation. The investigators subsequently showed that bretylium, a rarelyused antiarrhythmic drug that flattens res titution curves in cardiac myocytes, prevents wave break and, therefore, fibrillation. 107 The development of therapies that favorably alter these cardiac electrical restitution properties is a promising new approach to preventing fibrillation.
Several other systemsbased approaches to drug dis covery are moving away from the traditional target centric approach and instead focus on diseaserelated pathways and networks. This general approach has the advantage of not requiring specific knowledge of the actual target, or mechanism of action, of the drug candi date. One such approach uses quantitative network struc ture-activity relationships to identify molecules that shift disease pathways in a direction that is considered to be beneficial. 108 This approach involves the development of a diseasebased network that can be used to model the effects of module perturbation and couple it with high throughput profiling of the effects that specific molec ules have on individual pathways and on the network as a whole. These datasets are then integrated to identify candi date compounds that have the desired impact on the network and an acceptable safety profile. This approach remains theoretical at this point, but given the progress over the past 5 years in defining disease networks, such an approach is likely to have a major role in drug design in the future.
Conclusions
Common, complex cardiovascular diseases involve nonlinear genetic and environmental interactions that are difficult to dissect using reductionistic approaches. Technological advances have made global interrogation of these biologic systems possible, as well as application of the concepts of systems biology (particularly mathe matical modeling) to address their complexity. Systems based approaches have already revealed novel insights into cardiovascular disease and helped to develop new diagnostic and therapeutic modalities. Systemsgenetics approaches that integrate natural genetic variation with highthroughput technologies and mathematical model ing have been particularly informative. These novel approaches will likely dominate efforts to improve the health care of patients with cardiovascular disease in the future.
